China has taken the lead in CRISPR research as an oncology team in that country became the first to inject cells that contained edited genes using the technology.
Deal activity is rampant as Big Pharma gobbles up next-generation medicines and technologies to help overcome maturing pipelines and biosimilar threats.
For the pharmaceutical industry, 2016 brought new blockbusters onto the market to ease the pain of patent expirations.
The number of people with high blood pressure has almost doubled in 40 years to over 1.1 billion worldwide, scientists said, with the burden of the condition shifting from the rich to the poor.
A new type of heart drug developed by The Medicines Co. significantly lowered “bad” LDL cholesterol in high-risk patients with no major safety issues.
Amgen’s Repatha with statin therapy took “bad” LDL cholesterol down to extremely low levels and caused artery-clogging plaque decline after 18 months’ treatment.
Puma Biotechnology shares plummeted after the company disclosed patients taking its experimental breast cancer drug neratinib may require a second drug to prevent serious diarrhea.
Corbus Pharmaceuticals Holdings Inc. said its only drug outperformed a placebo in a mid-stage study involving patients with a form of systemic sclerosis.
Bristol-Myers Squibb Co.’s immuno-oncology treatment Opdivo has now been approved in five tumor types in under two years by the U.S. FDA.
Adult women in Puerto Rico were significantly more likely to develop Zika than men, researchers said, raising new questions about the potential role of sexual transmission of the virus from males to females.
Scientists in Britain have developed a type of HIV test using a USB stick that can give a fast and highly accurate reading of how much virus is in a patient’s blood.
AstraZeneca has given up on the idea of seeking early approval of its immunotherapy drug durvalumab in head & neck cancer using mid-stage Phase II trials data.
Shares of Arrowhead Pharmaceuticals were down after the company’s experimental hepatitis B drug, ARC-520, was placed on clinical hold by the U.S. FDA.
Shares of Bone Therapeutics dropped slightly after the company announced a change in leadership and ended plans to hold a clinical trial in the United States.
Scientists at Stanford University School of Medicine have used the CRISPR gene-editing tool to repair the gene that causes sickle cell disease in stem cells.
Biogen and Ionis Pharma announced that Spinraza (nusinersen) met its primary endpoint in its Phase III trial in later-onset spinal muscular atrophy (SMA).
For the second straight year, Sanofi was cited as one of the least transparent companies for clinical trial data.
Checkpoint inhibitors have become popular treatments for cancers, but a New England Journal of Medicine article may give physicians pause before prescribing them.
Merck & Co. published results from its Phase I clinical trial of verubecestat for Alzheimer’s disease in the journal Science Translational Medicine. The Phase I data provides information related mostly to the safety and activity of the drug.
Four patients have suffered serious adverse events in a clinical trial of an experimental hemophilia medicine from Roche, the Swiss group said, clouding prospects for its potential blockbuster product.
In the wake of a failed Phase IIb clinical trial, Opexa Therapeutics announced it will be laying off about 40 percent of its workforce.
Investors were not particularly happy with Gilead’s Q3 2016 report. In addition to sagging sales and revenue, it outlined a laundry list of failed clinical trials.